Natera, NeoGenomics Unit End Patent Suit Over Lung Cancer Test

Natera Inc. and Inivata Ltd. agreed to end their five-year clash over allegations that Inivata’s InVisionFirst-Lung test infringes patents related to personalized cancer monitoring and recurrence tracking, a court filing shows.

Natera and the NeoGenomics Inc. subsidiary agreed to dismiss all claims and counterclaims involving US Patent Nos. 10,262,755 and 10,597,709, though they left the door open for renewing allegations, according to their Feb. 20 joint filing Judge Gregory B. Williams approved Wednesday in the US District Court for the District of Delaware.

• The ‘755 patent expires in November 2034, and the ‘709 patent expires in April 2036, Bloomberg ...